QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
TSE:MBX

Microbix Biosystems (MBX) Stock Price, News & Analysis

C$0.36
-0.01 (-2.67%)
(As of 04:07 PM ET)
Today's Range
C$0.37
C$0.37
50-Day Range
C$0.37
C$0.43
52-Week Range
C$0.23
C$0.47
Volume
155,036 shs
Average Volume
81,399 shs
Market Capitalization
C$49.84 million
P/E Ratio
12.17
Dividend Yield
2.30%
Price Target
N/A
MBX stock logo

About Microbix Biosystems Stock (TSE:MBX)

Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.

MBX Stock Price History

MBX Stock News Headlines

Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Microbix’s Clot-Buster Drug Project Advances
Stocks in play: Microbix Biosystems Inc.
Microbix Biosystems Inc.
Microbix Announces Issuance of Stock Options
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Microbix Reports Record Results for Q1 Fiscal 2024
Microbix Schedules Release of Results for Q1 Fiscal 2024
Microbix Achieves Further QAPs Sales Record
Microbix Reports Results for Q4 & Full-Year Fiscal 2023
Microbix & Seegene USA Jointly Enhancing Lab Test Accuracy
Microbix Presenting at Florida Capital Event Conference
Microbix QAPs Supporting HPV Testing in Ireland
Microbix Biosystems Inc. (MBX)
Microbix Achieves New QAPs Sales Record
See More Headlines
Receive MBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Microbix Biosystems and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
C$3.72 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$22.42 million
Cash Flow
C$0.09 per share
Book Value
C$0.20 per share

Miscellaneous

Free Float
N/A
Market Cap
C$51.21 million
Optionable
Not Optionable
Beta
0.28
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Cameron L. Groome
    President, CEO & Director
  • Mr. James S. Currie
    Chief Financial Officer
  • Dr. Kenneth Hughes Ph.D.
    Chief Operating Officer
  • Dr. Mark Luscher Ph.D.
    Senior Vice President of Scientific Affairs
  • Mr. Philip Casselli
    Senior Vice President of Sales, Business Development & Marketing
  • Mr. Christopher B. Lobb
    Compliance Officer, General Counsel & Secretary

MBX Stock Analysis - Frequently Asked Questions

Should I buy or sell Microbix Biosystems stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Microbix Biosystems in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MBX shares.
View MBX analyst ratings
or view top-rated stocks.

How have MBX shares performed in 2024?

Microbix Biosystems' stock was trading at C$0.39 at the beginning of the year. Since then, MBX stock has decreased by 5.1% and is now trading at C$0.37.
View the best growth stocks for 2024 here
.

When is Microbix Biosystems' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our MBX earnings forecast
.

How were Microbix Biosystems' earnings last quarter?

Microbix Biosystems Inc. (TSE:MBX) released its quarterly earnings results on Wednesday, February, 14th. The company reported $0.02 earnings per share for the quarter. The company had revenue of $8.41 million for the quarter, compared to the consensus estimate of $8.10 million. Microbix Biosystems had a trailing twelve-month return on equity of 14.66% and a net margin of 16.57%.

What other stocks do shareholders of Microbix Biosystems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Microbix Biosystems investors own include TransAlta Renewables (RNW), Organigram (OGI), Dynavax Technologies (DVAX), Heat Biologics (HTBX), VEON (VEON), Vaxart (VXRT), Wajax (WJX), BlackBerry (BB) and Canadian Western Bank (CWB).

How do I buy shares of Microbix Biosystems?

Shares of MBX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:MBX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners